<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Cetuximab" /><meta name="IX" content="Cetuximab" /><title>Cetuximab: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5450-cetuximab.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5450-cetuximab.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5450-cetuximab.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5447-catumaxomab.htm" title="Previous: CATUMAXOMAB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5452-cetuximab.htm" title="Next: CETUXIMAB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a304006.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cetuximab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/18588-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Cetuximab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: C &gt; Interactions of Cetuximab</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="PHP5433-bevacizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs</p></div></li><li><a href="PHP5452-cetuximab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">CETUXIMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Cetuximab</p></div></li><li><a href="PHP5453-erbitux.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erbitux®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Cetuximab &gt; CETUXIMAB</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/18588-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cetuximab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02027.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cetuximab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; C &gt; CE</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-C74.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cetuximab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; C</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E2E3E0R0D1689.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Cetuximab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; C</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Cetuximab</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Cetuximab</strong> is licensed for the treatment of metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as cmbination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated (but see NICE guidance below). Cetuximab is also licensed, in combination with radiotherapy, for the treatment of locally advanced squamous cell cancer of the head and neck and in combination with platinum-based chemotherapy for recurrent or metastatic squamous cell cancer of the head and neck (but see NICE guidance below).</p><p>Cetuximab is given by intravenous infusion. Patients must receive an antihistamine and a corticosteroid before infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist.</p><div class="cI"><p class="cAE">MHRA/CHM advice</p> <h3 class="cT">Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)</h3><p id="PHP18413">Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.</p> </div><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (January 2010) that cetuximab (<em>Erbitux</em>®) is accepted for restricted use within NHS Scotland, in combination with chemotherapy, for metastatic colorectal cancer in patients with tumours expressing epidermal growth factor; it is restricted to patients with non-resectable metastases confined to the liver, who have not previously received chemotherapy.</p><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008)</h3><p>Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009)</h3><p>Cetuximab in combination with platinum-based chemotherapy is <strong>not</strong> recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)</h3><p>Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:</p><ul><li><p>the primary tumour has been resected or is potentially operable;</p> </li><li><p>the metastatic disease is confined to the liver and is unresectable; and</p> </li><li><p>the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.</p> </li></ul><p>In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.</p><p>In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.</p><p>Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.</p></div><div class="cI"><p class="cAE">NICE guidance</p> <h3 class="cT">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</h3><p id="PHP18395">Cetuximab monotherapy or combination chemotherapy is <strong>not </strong>recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.</p><p>Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is <strong>not</strong> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy; see also NICE guidance <a title="Bevacizumab (NICE guidance)" href="PHP5433-bevacizumab.htm#PHP5435">Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)</a></p><p>Panitinumab monotherapy is <strong>not</strong> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.</p> </div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5452-cetuximab"><a href="PHP5452-cetuximab.htm" title="CETUXIMAB">CETUXIMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5447-catumaxomab.htm">Previous: CATUMAXOMAB</a> | <a class="top" href="PHP5450-cetuximab.htm#">Top</a> | <a accesskey="]" href="PHP5452-cetuximab.htm">Next: CETUXIMAB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>